Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
69.31
+0.58 (0.84%)
At close: Nov 13, 2026, 4:00 PM EST
69.61
+0.30 (0.44%)
After-hours: Nov 13, 2026, 7:58 PM EST
Royalty Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,617 | 2,378 | 2,264 | 2,355 | 2,237 | 2,289 | |
Revenue Growth | 11.36% | 5.06% | -3.86% | 5.24% | -2.28% | 7.87% |
Cost of Revenue | 5.52 | -295.84 | 732.46 | 560.66 | 904.24 | 452.84 |
Gross Profit | 2,611 | 2,674 | 1,531 | 1,794 | 1,333 | 1,837 |
Selling, General & Admin | 665.35 | 573.48 | 236.67 | 249.75 | 227.3 | 182.83 |
Research & Development | 251.3 | 452 | 2 | 52 | 177.11 | 200.08 |
Amortization of Goodwill & Intangibles | - | - | - | - | 5.67 | 23 |
Operating Expenses | 925.72 | 1,115 | 238.67 | 301.75 | 410.08 | 405.91 |
Operating Income | 1,686 | 1,560 | 1,292 | 1,492 | 922.89 | 1,431 |
Interest Expense | -372 | -307.66 | -225.51 | -187.19 | -187.96 | -166.14 |
Interest & Investment Income | 23.77 | 33.59 | 47.34 | 72.29 | 78.34 | 53.54 |
Earnings From Equity Investments | 39.07 | 29.09 | 29.61 | 28.88 | -8.97 | -19.49 |
Other Non Operating Income (Expenses) | -13.75 | -14.35 | -7.53 | -24.03 | 81.86 | -27.21 |
EBT Excluding Unusual Items | 1,363 | 1,300 | 1,136 | 1,382 | 886.15 | 1,271 |
Gain (Loss) on Sale of Investments | 0.84 | 24.01 | 194.46 | 317.98 | -40.26 | -30.21 |
Asset Writedown | -219.8 | - | - | - | -615.83 | - |
Pretax Income | 1,173 | 1,324 | 1,331 | 1,700 | 230.06 | 1,241 |
Earnings From Continuing Operations | 1,173 | 1,324 | 1,331 | 1,700 | 230.06 | 1,241 |
Minority Interest in Earnings | -500.84 | -553.25 | -471.83 | -565.25 | -187.23 | -621.47 |
Net Income | 672.45 | 770.95 | 858.98 | 1,135 | 42.83 | 619.73 |
Net Income to Common | 672.45 | 770.95 | 858.98 | 1,135 | 42.83 | 619.73 |
Net Income Growth | -11.98% | -10.25% | -24.31% | 2549.50% | -93.09% | 25.15% |
Shares Outstanding (Basic) | 439 | 430 | 448 | 448 | 438 | 415 |
Shares Outstanding (Diluted) | 476 | 564 | 594 | 603 | 438 | 415 |
Shares Change | -16.87% | -4.99% | -1.46% | 37.66% | 5.59% | 10.48% |
EPS (Basic) | 1.53 | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 |
EPS (Diluted) | 1.53 | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 |
EPS Growth | -12.48% | -6.83% | -24.54% | 2490.74% | -93.44% | 12.97% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share | 0.925 | 0.880 | 0.840 | 0.800 | 0.760 | 0.680 |
Dividend Growth | 6.32% | 4.76% | 5.00% | 5.26% | 11.77% | 126.67% |
Gross Margin | 99.79% | 112.44% | 67.64% | 76.19% | 59.58% | 80.22% |
Operating Margin | 64.41% | 65.58% | 57.10% | 63.37% | 41.25% | 62.49% |
Profit Margin | 25.70% | 32.42% | 37.95% | 48.20% | 1.92% | 27.07% |
EBITDA | 1,690 | 1,563 | - | 1,498 | 928.56 | 1,454 |
EBITDA Margin | 64.60% | 65.74% | - | 63.61% | 41.50% | 63.50% |
D&A For EBITDA | 4.88 | 3.85 | - | 5.67 | 5.67 | 23 |
EBIT | 1,686 | 1,560 | 1,292 | 1,492 | 922.89 | 1,431 |
EBIT Margin | 64.41% | 65.58% | 57.10% | 63.37% | 41.25% | 62.49% |
Revenue as Reported | 2,617 | 2,378 | 2,264 | 2,355 | 2,237 | 2,289 |